Ondine Biomedical eyes US market expansion
LONDON: Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial therapies, announced significant milestones in its 2024 annual report, positioning the company for accelerated growth in 2025 and beyond. Key achievements include robust commercial expansion, strategic partnerships and the…